1. Home
  2. ONCO vs PPCB Comparison

ONCO vs PPCB Comparison

Compare ONCO & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$0.82

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Logo Propanc Biopharma Inc.

PPCB

Propanc Biopharma Inc.

HOLD

Current Price

$1.02

Market Cap

2.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONCO
PPCB
Founded
2018
2007
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
2.6M
IPO Year
2021
2011

Fundamental Metrics

Financial Performance
Metric
ONCO
PPCB
Price
$0.82
$1.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
172.5K
3.2M
Earning Date
06-11-2026
05-16-2026
Dividend Yield
N/A
N/A
EPS Growth
22.80
N/A
EPS
N/A
N/A
Revenue
$815,371.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.09
$0.06
52 Week High
$6.73
$6.79

Technical Indicators

Market Signals
Indicator
ONCO
PPCB
Relative Strength Index (RSI) 46.44 44.71
Support Level $0.69 $0.90
Resistance Level $1.01 $1.38
Average True Range (ATR) 0.05 0.29
MACD 0.00 -0.01
Stochastic Oscillator 56.77 1.59

Price Performance

Historical Comparison
ONCO
PPCB

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Share on Social Networks: